Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Isolated Limb Perfusion for In-Transit Melanoma Metastases
2023-509265-21-00Phase 2Authorised
- Sponsor
- Region Västra Götaland
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in melanoma comparing ILP + nivolumab with ILP + placebo (2 arms). Primary endpoint: Complete response rate at 3 months after isolated limb perfusion. Planned start Feb 2024; status: authorised.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2023-509265-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509265-21-00.